Clinical results of drug eluting stents compared to bare metal stents for patients with ST elevation acute myocardial infarction

References

• Weaver WD, Simes RJ, Betriu A, Zijlstra F, Garcia E, Grinfeld L, et al. Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review. JAMA 1997; 278: 2093–8
   PubMed Web of Science ®Google Scholar
• Zijlstra F, Hoorntje JCA, de Boer M-J, Reiffers S, Miedema K, Ottervanger JP, et al. Long- term benefit of primary angioplasty as compared with thrombolytic therapy for acute myocardial infarction. N Engl J Med. 1999; 341: 1413–9
   PubMed Web of Science ®Google Scholar
• The global use of strategies to open occluded coronary arteries in acute coronary syndromes (GUSTO IIb) angioplasty sub study investigators. A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. N Engl J Med. 1997;336:1621–8.
   PubMed Web of Science ®Google Scholar
• Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomized trials. Lancet 2003; 361: 13–20
   PubMed Web of Science ®Google Scholar
• Boersma E. Primary coronary angioplasty vs. Thrombolysis group. Does time matter? A pooled analysis of randomized clinical trials comparing primary percutaneous coronary intervention and in-hospital fibrinolysis in acute myocardial infarction patients. Eur Heart J. 2006; 27: 779–88
   PubMed Web of Science ®Google Scholar
• McKeage K, Murdoch D, Goa KL. The sirolimus-eluting stent: a review of its use in the treatment of coronary artery disease. Am J Cardiovasc Drugs 2003; 3: 211–30
   PubMedGoogle Scholar
• Silber S. Paclitaxel-eluting stents: are they all equal? An analysis of six randomized controlled trials in de novo lesions of 3,319 patients. J Interv Cardiol. 2003; 16: 485–90
   PubMedGoogle Scholar
• Stone GW, Grines CL, Cox DA, Garcia E, Tcheng JE, Griffin JJ, et al. Controlled abciximab and device investigation to lower late angioplasty complications (CADILLAC) investigators … Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med. 2002; 346: 957–66
   PubMed Web of Science ®Google Scholar
• Grines CL, Cox DA, Stone GW, Garcia E, Mattos LA, Giambartolomei A, et al. Coronary angioplasty with or without stent implantation for acute myocardial infarction. Stent primary angioplasty in myocardial infarction study group. N Engl J Med. 1999; 341: 1949–56
   PubMed Web of Science ®Google Scholar
• Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, et al. RAVEL Study Group. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002; 346: 1773–80
   PubMed Web of Science ®Google Scholar
• Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, et al. TAXUS-IV Investigators. A polymer based paclitaxel-eluting stent in patient with coronary artery disease. N Engl J Med. 2004; 350: 221–31
   PubMed Web of Science ®Google Scholar
• Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, et al. SIRIUS Investigators. Sirolimus-eluting stent versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003; 349: 1315–23
   PubMed Web of Science ®Google Scholar
• Schofer J, Schluter M, Gershlick AH, Wijns W, Garcia E, Schampaert E, et al. E-SIRIUS Investigators. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomized controlled trial (E-SIRIUS). Lancet 2003; 362: 1093–9
   PubMed Web of Science ®Google Scholar
• Waugh J, Wagstaff AJ. The paclitaxel (TAXUS)-eluting stent: a review of its use in the management of de novo coronary artery lesions. Am J Cardiovasc Drugs 2004; 4: 257–68
   PubMedGoogle Scholar
• Kuchulakanti PK, Chu WW, Torguson R, Ohlmann P, Rha SW, Clavijo LC, et al. Correlates and long term outcomes of angiographically proven stent thrombosis with Sirolimus and Paclitaxel- eluting stents. Circulation 2006; 113: 1108–13
   PubMed Web of Science ®Google Scholar
• Lemos PA, Saia F, Hofma SH, Daemen J, Ong AT, Arampatzis CA, et al. Short and long term clinical benefit of Sirolimus-eluting stents copared to conventional bare stents for patients acute myocardial infarction. J Am Coll Cardiol. 2004; 18;43: 704–8
   Google Scholar
• Valgimigli M, Percoco G, Malagutti P, Campo G, Ferrari F, Barbieri D, et al. STRATEGY Investigators. Tirofiban and sirolimus-eluting stent vs. abciximab and bare-metal stent for acute myocardial infarction: a randomized trial. JAMA 2005; 293: 2109–17
   PubMed Web of Science ®Google Scholar
• Cheneau E, Rha SW, Kuchulakanti PK, Stabile E, Kinnaird T, Torguson R, et al. Impact of Sirolimus eluting stents on outcomes of patients treated for acute myocardial infarction by primary angioplasty. Catheter Cardiovasc Interv. 2005; 65: 469–72
   PubMedGoogle Scholar
• Saia F, Lemos PA, Lee CH, Arampatzis CA, Hoye A, Degertekin M, et al. Sirolimus-eluting stent implantation in ST-elevation acute myocardial infarction: A clinical and angiographic study. Circulation 2003; 108: 1927–9
   PubMed Web of Science ®Google Scholar
• Spaulding C, Henry P, Teiger E, Beatt K, Bramucci E, Carrie D, et al. TYPHOON Investigators. Sirolimus–eluting stents versus uncoated stents in acute myocardial infarction. N Engl J Med. 2006; 355: 1093–104
   PubMed Web of Science ®Google Scholar
• Laarman GJ, Suttorp MJ, Dirksen MT, van Heerebeek L, Kiemeneij F, Slagboom T, et al. Paclitaxel—eluting versus uncoated stents in primary percutaneous coronary intervention. N Engl J Med. 2006; 355: 1105–13\
   PubMed Web of Science ®Google Scholar
• Wessely R, Schomig A, Kastrati A. Sirolimus and paclitaxel on polymer based drug eluting stents: similar but different. J Am Coll. Cardiol. 2006; 47: 708–14
   Google Scholar
• Halkin A, Singh M, Nikolsky E, Grines CL, Tcheng JE, Garcia E, et al. Prediction of mortality after primary percutaneous coronary intervention for acute myocardial infarction: the CADILLAC risk score. J Am Coll Cardiol. 2005; 45: 1397–405
   PubMed Web of Science ®Google Scholar
• Spertus JA, Kettelkamp R, Vance C, Decker C, Jones PG, Rumsfeld JS, et al. Prevalence, predictors and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation 2006; 113: 2803–9
   PubMed Web of Science ®Google Scholar
• Wang F, Stouffer GA, Waxman S, Uresky BF. Late coronary stent thrombosis: Early vs. late stent thrombosis in the stent era. Catheter Cardiovasc Interv. 2002; 55: 142–7
   PubMed Web of Science ®Google Scholar
• Colombo A, Drzewiecki J, Banning A, Grube E, Hauptmann K, Silber S, et al. TAXUS II Study Group. Randomized study to assess the effectiveness of slow- and moderate-release polymer based paclitaxel-eluting stents for coronary artery lesions. Circulation 2003; 108: 788–94
   PubMed Web of Science ®Google Scholar
• Virmani R, Guagliumi G, Farb A, Musumeci G, Grieco N, Motta T, et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent. Should we be cautious?. Circulation 2004; 109: 701–5
   PubMed Web of Science ®Google Scholar
• Van de Werf F. Drug-eluting stents in acute myocardial infarction. N Engl J Med. 2006; 355: 1169–70
   PubMedGoogle Scholar